Stockscreener 앱 받기
4.15
1.22%
0.05
시간 외 거래:
4.47
0.32
+7.71%
전일 마감가:
$4.10
열려 있는:
$4.14
하루 거래량:
305.38K
Relative Volume:
0.91
시가총액:
$2.27M
수익:
-
순이익/손실:
$-13.47M
주가수익비율:
-0.1066
EPS:
-38.9215
순현금흐름:
$-8.38M
1주 성능:
-22.28%
1개월 성능:
+499.71%
6개월 성능:
-47.93%
1년 성능:
-76.51%
1일 변동 폭
$3.86
$4.20
1주일 범위
$3.45
$4.90
52주 변동 폭
$0.52
$19.91
Artelo Biosciences Inc Stock (ARTL) Company Profile
명칭
Artelo Biosciences Inc
전화
858-925-7049
주소
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
4.15 | 2.97M | 0 | -13.47M | -8.38M | -38.92 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2021-02-12 | 개시 | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc 주식(ARTL)의 최신 뉴스
Artelo Biosciences reports positive ART27.13 results in neuropathic pain model - scanx.trade
Artelo Biosciences at H.C. Wainwright: early data, tight cash By Investing.com - Investing.com South Africa
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference - ca.finance.yahoo.com
Artelo Biosciences data supports ART26.12 for spinal cord injury pain - scanx.trade
Artelo Biosciences Stock Price Forecast. Should You Buy ARTL? - StockInvest.us
Artelo Biosciences Inc. Warrant (ARTLW) Peer Comparison – Compare with Others - Value Research
Artelo Biosciences Inc. Warrant (ARTLW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Artelo Biosciences Inc. Warrant (ARTLW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Artelo Biosciences Inc (NASDAQ: ARTL) Share Price, ARTL Stock News, ARTL Share Price & Updates - kalkine.ca
Artelo Biosciences Inc. (ARTL) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Artelo Biosciences To Carry Out 1-for-9 Reverse Stock Split On August 31st, 2026 - Moomoo
Artelo Biosciences Inc. (ARTL) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Artelo Biosciences announces 1-for-9 reverse stock split - Investing.com India
Artelo Biosciences (Nasdaq: ARTL) to trade post-split Aug 31 - Stock Titan
Artelo Biosciences announces 1-for-9 reverse stock split By Investing.com - Investing.com Canada
Artelo Biosciences Announces Reverse Stock Split - Barchart.com
Artelo (ARTL) Technicals: Declines 2.86% to $0.69 at the Close; Range View - vinanet.vn
Armistice Capital Exits Artelo Biosciences (ARTL) Position in Co - GuruFocus
Artelo Biosciences wins Japan patent allowance for ART27.13 commercial formulation - Bitget
Artelo Biosciences (ARTL) Secures Japanese Patent for ART27.13, Extending IP Protection to 2041 - GuruFocus
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - The Manila Times
Artelo (ARTL) Results at a Glance: The Latest Report Adds New Financial Reference Points at the Close; Share Response: Shares Move 1.25% Up in the Latest ReadingEarnings Preview - vinanet.vn
Artelo Biosciences (ARTL) Q2 2026 Earnings: Clinical-Stage Firm Posts $0.89 Per Share Loss as Shares Fall 8.76%Geographic Revenue Trends - dars.gov.et
Artelo Biosciences (ARTL) Secures Patent Allowance for ART27.13 Commercial Formulation - GuruFocus
Artelo Biosciences Receives a Notice of Allowance from the - GlobeNewswire
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies - Yahoo Finance
ARTL Q2 2026 Earnings: Reported EPS of -$0.89 Reflects Continued Development FocusROIC Trend Report - vinanet.vn
ARTL Q2 2026 Earnings: Reported Loss of -$0.89 Per Share Highlights Clinical-Stage InvestmentGuidance vs Actual - vinanet.vn
Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A - Stock Titan
Artelo Biosciences Releases Q2 2026 Financial Results - news.alphastreet.com
Artelo Biosciences Q2 Results: EPS loss narrows 95% YoY to $(0.89) - scanx.trade
Artelo Biosciences (ARTL) investors disclose 4.8% stake via Intracoastal warrant - Stock Titan
Artelo Biosciences Q2 Net Income USD -2.4 Mil - Moomoo
Artelo Plans Q4 Trial After ART26.12 Matches Naproxen for Pain - Stock Titan
Artelo Biosciences (ARTL) trims liabilities, boosts cash amid $5.4M H1 loss - Stock Titan
Artelo Biosciences (ARTL) Advances 6.34% to $0.75 as Micro-Cap Biotech Tests Key ResistanceDebt Free Companies - vinanet.vn
Artelo Biosciences doses first patient in Phase 2 glaucoma trial of ART27.13 - Bitget
Artelo doses first patient in glaucoma study for ART27.13 - Investing.com
Artelo Tests an Oral Cannabinoid for Glaucoma Eye Pressure - Stock Titan
Price to book forward of Artelo Biosciences, Inc. – NASDAQ:ARTL - TradingView
Price to sales forward of Artelo Biosciences, Inc. – NASDAQ:ARTL - TradingView
Enterprise value to EBIT forward of Artelo Biosciences, Inc. – NASDAQ:ARTL - TradingView
Artelo Biosciences (ARTL) Slips to $0.73 as Biotech Names Face Renewed Selling PressureBlue Chip Entry Points - vinanet.vn
ARTL Q2'26 Earnings: revenue estimate is 0 USD - TradingView
ARTL Q4 2025 Earnings: 97.5% EPS Surprise as Net Loss Narrowly Beats EstimatesEPS Surprise History - vinanet.vn
Price to earnings forward of Artelo Biosciences, Inc. – NASDAQ:ARTL - TradingView
Artelo Biosciences, Inc. Revenue Breakdown – NASDAQ:ARTL - TradingView
ARTL|Artelo Biosciences Inc|Price:1.020|Chg%:-0.040 - TradingKey
Artelo Biosciences (ARTL) Edges Higher Near Resistance: Key Levels to WatchGrowth Factor - vinanet.vn
Artelo Biosciences Inc (ARTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Artelo Biosciences Inc (ARTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.15%
자본화:
|
볼륨(24시간):